Cross-source identity
National Provider Identifier 1407895253 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1407895253 | Registry identity — dermatologist, taxonomy 207N00000X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1407895253 | 401 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1407895253 | 31 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity 25e420f1… | Canonical resolved node · 4 identifier(s) · 6 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $85,461 | 45 |
| Consulting Fee | $49,425 | 25 |
| Travel and Lodging | $7,512 | 13 |
| Food and Beverage | $7,296 | 314 |
| Education |
| Manufacturer | Amount | Records |
|---|---|---|
| Arcutis Biotherapeutics, Inc. | $51,683 | 49 |
| Amgen Inc. | $40,699 | 45 |
| Abbvie Inc. | $32,691 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Skyrizi Pen(Risankizumab-Rzaa) | 25 | $508,798 |
| Otezla(Apremilast) | 67 | $312,200 |
| Tremfya(Guselkumab) | 23 | $285,431 |
| Humira(Cf) Pen(Adalimumab) | 12 | $78,752 |
| Zoryve(Roflumilast) | 26 | $34,242 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Janssen Biotech, Inc. (PA) | cms_open_payments |
| ← pays | Novartis Pharmaceuticals Corporation (NJ) | cms_open_payments |
| ← pays | Medimetriks Pharmaceuticals, Inc. (NJ) | cms_open_payments |
| ← pays | Biofrontera Inc. (MA) | cms_open_payments |
| ← pays | E.R. Squibb & Sons, L.L.C. (NJ) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| 4 |
| 87 |
| Janssen Biotech, Inc. | $15,288 | 48 |
| Incyte Corporation | $7,048 | 17 |